United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $4.16, $0.57 better than the analyst estimate of $3.59. Revenue for the quarter came in at $444.7 million versus the consensus estimate of $421.45 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.